胸腺法新对矽肺合并肺结核患者T淋巴细胞亚群的影响及临床意义

Abstract
Figure/Table
References (15)
Related Citation (12)

Download: PDF (0 KB) HTML (38 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the influence and clinical significance of Thymalfasin on T-lymphocyte subsets of patients with silicosis combined with tuberculosis.Methods A total of 60 patients with silicosis combined with tuberculosis in General Hospital of Pingxiang Mining Group Co.,Ltd.were selected as the research subjects.They were divided into two groups according to random number table method,30 cases in each group.The control group was given routine chemotherapy regimen,and research group added Thymalfasin.The negative conversion ratio at different time after treatment were compared between two groups.After treatment for 6 months,the efficacy,CD4+,CD8+,CD4+/CD8+,adverse reactions were compared.Results After treatment for 3， 6 and 12 months,the negative conversion ratio of research group was higher than that of control group;after treatment for 6 months,the cure rate of research group was higher than that of control group,the total incidence of adverse reactions in research group was lower than that in control group,the differences were statistically significant (P<0.05).There were no statistical differences in the levels of CD4+,CD4+/CD8+ and CD8+ between two groups before treatment (P＞0.05);after treatment for 6 months,the levels of CD4+ and CD4+/CD8+ in research group were higher than those in control group,and the level of CD8+ in research group was lower than that in control group,the differences were statistically significant (P<0.05).Conclusion Thymalfasin and routine chemotherapy in treatment of silicosis combined with tuberculosis has significant effect,it can increase negative conversion ratio and the levels of T-lymphocyte subsets,which has higher safety.

Key words： Silicosis combined with tuberculosis Thymalfasin T-lymphocyte subsets

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WU Bo
	HE Dan
	ZHANG Yi
	TANG Hai-yun
	LIU Xi-dong

Cite this article:

WU Bo,HE Dan,ZHANG Yi, et al. Influence and clinical significance of Thymalfasin on T-lymphocyte subsets of patients with silicosis combined with tuberculosis[J]. 中国当代医药, 2020, 27(30): 31-33.

URL:

https://www.dangdaiyiyao.com/EN/ OR https://www.dangdaiyiyao.com/EN/Y2020/V27/I30/31

[1]	邓岚兰，杨新婷，贾俊楠，等.2012～2016年北京市胸科医院肺结核合并症患者的回顾性分析[J].疾病监测，2018，33（4）：320-323.
[2]	刘静，封琳敏，唐慧晶，等.天津市2001 至2015年矽肺流行病学特征[J].中华劳动卫生职业病杂志，2019，37（5）：366-369.
[3]	周为鸿.结核诊断金标准探讨[J].实用诊断与治疗杂志，2006，20（10）：741-742.
[4]	李德鸿.尘肺病诊断标准[C].2011 尘肺病影像诊断新进展研讨会，2011.
[5]	刘忠鑫.联合用药治疗矽肺的远期疗效观察[J].中国医药指南，2017，15（26）：34-35.
[6]	李强，马丽萍，高孟秋.27例利福平依赖肺结核的临床特点及治疗结果分析[[J].北京医学，2017，39（7）：708-711.
[7]	刘亚，刘娴，余志斌，等.矽肺合并慢性阻塞性肺疾病患者的肺功能及血气分析[J].中国当代医药，2018，25（6）：111-113.
[8]	于斌.老年矽肺合并肺结核临床分析[J].中国现代药物应用，2016，10（18）：67-68.
[9]	宛月.人工肝配合胸腺肽α1 在晚期肝衰竭患者免疫调节中的疗效分析[J].广西医科大学学报，2019，36（10）：1623-1626.
[10]	巢益群，周杰，黄洁媛，等.免疫治疗对老年重症肺炎临床疗效的影响[J].中国老年学杂志，2019，39（6）：1348-1350.
[11]	王华兵，董芳，徐玲文.胸腺肽α1 对大鼠脓毒症的影响[J].中华麻醉学杂志，2019，39（7）：877-880.
[12]	吴小霞，辛朝雄，杨俭，等.环丝氨酸联合胸腺肽干预耐多药肺结核研究[J].热带医学杂志，2017，17（7）：936-939，944.
[13]	付康，宋晓燕，张天钰.含环丝氨酸联合胸腺肽方案治疗耐多药肺结核的疗效及安全性[J].临床和实验医学杂志，2018，17（24）：2643-2646.
[14]	刘顶坤，刘海清，程国玲，等.胸腺肽在复治肺结核的临床疗效[J].临床肺科杂志，2019，24（7）：1289-1292.
[15]	何兵.胸腺肽治疗难治性肺结核临床观察[J].临床肺科杂志，2015，20（3）：558-560.